These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 31424659)

  • 1. Interlaboratory concordance in HER2 testing: Results of a Serbian ring-study.
    Ivkovic-Kapic T; Knezevic Usaj S; Moldvaji E; Jovanic I; Milovanovic Z; Milentijevic M; Tatic S; Mitrovic S; Stojiljkovic M; Cvetanovic A
    J BUON; 2019; 24(3):1045-1053. PubMed ID: 31424659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of TMA for interlaboratory validation of FISH testing for detection of HER2 gene amplification in breast cancer.
    Diaz LK; Gupta R; Kidwai N; Sneige N; Wiley EL
    J Histochem Cytochem; 2004 Apr; 52(4):501-7. PubMed ID: 15034001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
    Bilous M; Morey A; Armes J; Cummings M; Francis G
    Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH.
    Li-Ning-T E; Ronchetti R; Torres-Cabala C; Merino MJ
    Int J Surg Pathol; 2005 Oct; 13(4):343-51. PubMed ID: 16273190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.
    Mehrazma M; Kalantari E; Rezvani H; Bahar B; Basi A; Razavi SM; Rakhshani N
    Asian Pac J Cancer Prev; 2015; 16(17):7695-700. PubMed ID: 26625783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardization of HER2 testing: results of an international proficiency-testing ring study.
    Dowsett M; Hanna WM; Kockx M; Penault-Llorca F; Rüschoff J; Gutjahr T; Habben K; van de Vijver MJ
    Mod Pathol; 2007 May; 20(5):584-91. PubMed ID: 17396141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey.
    Fitzgibbons PL; Murphy DA; Dorfman DM; Roche PC; Tubbs RR;
    Arch Pathol Lab Med; 2006 Oct; 130(10):1440-5. PubMed ID: 17090184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.
    Hwang CC; Pintye M; Chang LC; Chen HY; Yeh KY; Chein HP; Lee N; Chen JR
    Histopathology; 2011 Nov; 59(5):984-92. PubMed ID: 22092410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
    Perez EA; Suman VJ; Davidson NE; Martino S; Kaufman PA; Lingle WL; Flynn PJ; Ingle JN; Visscher D; Jenkins RB
    J Clin Oncol; 2006 Jul; 24(19):3032-8. PubMed ID: 16809727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.
    Egervari K; Szollosi Z; Nemes Z
    Appl Immunohistochem Mol Morphol; 2008 Oct; 16(5):510-1. PubMed ID: 18580496
    [No Abstract]   [Full Text] [Related]  

  • 11. Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.
    Wixom CR; Albers EA; Weidner N
    Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):248-51. PubMed ID: 15551739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
    Shen DH; Wang FH; Yu YZ
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 testing in breast carcinoma: very low concordance rate between reference and local laboratories in Brazil.
    Wludarski SC; Lopes LF; Berto E Silva TR; Carvalho FM; Weiss LM; Bacchi CE
    Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):112-8. PubMed ID: 20930616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.
    Dyhdalo KS; Fitzgibbons PL; Goldsmith JD; Souers RJ; Nakhleh RE
    Arch Pathol Lab Med; 2014 Jul; 138(7):876-84. PubMed ID: 24978913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of HER2 detection methods between central and regional laboratories in Greece.
    Papadopoulos S; Kouvatseas G; Skarlos D; Malamos N; Delliou E; Saratsiotou I; Ardavanis A; Mavroudis D; Skarpidi E; Arapantoni P; Karyda I; Patakioyta F; Aravantinos G; Razis E; Fountzilas G; Kosmidis P
    Clin Breast Cancer; 2007 Oct; 7(10):784-90. PubMed ID: 18021480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.
    Powell WC; Hicks DG; Prescott N; Tarr SM; Laniauskas S; Williams T; Short S; Pettay J; Nagle RB; Dabbs DJ; Scott KM; Brown RW; Grogan T; Roche PC; Tubbs RR
    Appl Immunohistochem Mol Morphol; 2007 Mar; 15(1):94-102. PubMed ID: 17536315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoplex LightCycler polymerase chain reaction quantitation of the HER2 gene for quality assurance of HER2/neu testing by immunohistochemistry and fluorescence in situ hybridization.
    Layfield LJ; Willmore-Payne C; Isom G; Holden JA
    Appl Immunohistochem Mol Morphol; 2008 Dec; 16(6):562-7. PubMed ID: 18948825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
    Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization.
    Loring P; Cummins R; O'Grady A; Kay EW
    Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):194-200. PubMed ID: 15894935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
    Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
    Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.